Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IIIB-C Melanoma Clear all
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced May 22, 2026, 1:30 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
Interventions
Daromun, Surgery, Adjuvant therapy
Drug · Procedure
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
19
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
tyrosinase peptide, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery, Trametinib
Drug · Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced May 22, 2026, 1:30 AM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Melanoma
Interventions
ipilimumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Melanoma
Interventions
Sylatron, Yervoy
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced May 22, 2026, 1:30 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Stage IIIB-C Melanoma
Interventions
Vemurafenib and Cobimetinib
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Melanoma
Interventions
nivolumab, ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma, Lymph Node Cancer
Interventions
CMP-001, Nivolumab
Drug · Biological
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acral Lentiginous Malignant Melanoma, Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Miami Beach, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced May 22, 2026, 1:30 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Trametinib
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 22, 2026, 1:30 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
Interventions
Binimetinib, Conventional Surgery, Encorafenib, Fluorothymidine F-18
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Ann Arbor, Michigan • City of Saint Peters, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Nivolumab, Placebo matching Ipilimumab, Placebo matching Nivolumab
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
15 Years and older
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
35
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced May 22, 2026, 1:30 AM EDT